Taking on board potential Zantac litigation headwinds
16/08/22 -"To factor in the negative investor sentiment regarding the potential adverse implications of the Zantac trial in the US (expected to start by end-Aug 2022), we have injected a discount of 30% into ..."
Pages
62
Language
English
Published on
16/08/22
You may also be interested by these reports :
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...